

Integra LifeSciences Grows Its Presence in the Spinal Deformity Market

Expands Product Offering With Two New Systems

PLAINSBORO, N.J., Nov. 2, 2011 (GLOBE NEWSWIRE) -- <u>Integra LifeSciences Holdings Corporation</u> (Nasdaq:IART) today announced the expanded market introduction of the Daytona[™] Deformity Spinal System, which was previously released on a limited basis in 2010, and the limited market introduction of the Integra[™] Stainless Steel Spinal System. The addition of these two products enhances Integra's ability to offer surgeons versatile solutions for spinal deformity correction procedures.

"Deformity correction is a specialized segment of the spinal fixation market, where cases are often complex and outcomes may be life-changing," said Raymund Woo, MD, from Orlando, Florida. "Depending on the patient's condition, different rod materials are needed, including titanium alloy, stainless steel or cobalt chrome. Now that Integra offers these three rod material options, it demonstrates their desire to be a strong solutions provider in this market."

The Daytona™ Deformity System is designed to address standard to complex deformity cases for adult patients. It combines unique implant designs, materials and innovative instrumentation to create a highly versatile system. The screws feature extended travel housings for 30mm of built in rod reduction, and the intuitive instrumentation accommodates multiple derotation techniques.

"The flexibility of having both polyaxial and uniplanar screws in the Daytona™ system is critical for my patients," said Dave Siambanes, DO, from Tampa, Florida. "Derotation maneuvers require lateral force, and uniplanar screws provide this."

For surgeons who prefer a stiffer and stronger construct, Integra's stainless steel system for complex deformity corrections features multi-functional instrumentation and supports a variety of correction procedures. The system offers a 6.35mm diameter rod, among the highest strength and stiffness available on the market. Its derotation towers allow for both segmental and enbloc correction, and simultaneously function as rod reducers.

"Our new product introductions underscore Integra's commitment to provide surgeons with comprehensive solutions for deformity correction procedures," said Kirt Stephenson, Integra's President, U.S. Spine. "We will continue to focus on the needs of surgeons and seek their input as we grow our presence in the spine market."

About Integra

<u>Integra LifeSciences</u>, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit <u>www.integralife.com</u>

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Gianna Sabella

Director, Corporate Communications

(609) 936-2389

gianna.sabella@integralife.com